Zacks Research Upgrades Glaukos (NYSE:GKOS) to “Strong-Buy”

Glaukos (NYSE:GKOS) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Wednesday, Zacks reports.

Other analysts also recently issued research reports about the company. UBS Group began coverage on Glaukos in a research note on Tuesday, July 28th. They set a “neutral” rating and a $150.00 target price on the stock. BTIG Research upped their price target on Glaukos from $205.00 to $234.00 and gave the stock a “buy” rating in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a report on Thursday, October 15th. Piper Sandler reiterated an “overweight” rating and set a $240.00 price objective (up from $195.00) on shares of Glaukos in a research report on Thursday. Finally, Wells Fargo & Company boosted their target price on shares of Glaukos from $178.00 to $226.00 and gave the stock an “overweight” rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $216.71.

Glaukos Stock Up 32.7%

GKOS opened at $240.81 on Wednesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04. Glaukos has a fifty-two week low of $80.90 and a fifty-two week high of $243.71. The firm’s fifty day moving average is $172.26 and its 200 day moving average is $140.51. The stock has a market cap of $14.20 billion, a price-to-earnings ratio of -81.91 and a beta of 0.69.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.57. The business had revenue of $211.03 million during the quarter, compared to analyst estimates of $168.04 million. Glaukos had a negative return on equity of 0.98% and a negative net margin of 24.60%. Glaukos’s revenue for the quarter was up 58.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.16) EPS. On average, sell-side analysts forecast that Glaukos will post -0.32 earnings per share for the current fiscal year.

Insider Activity at Glaukos

In other Glaukos news, COO Joseph Gilliam sold 60,000 shares of Glaukos stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the sale, the chief operating officer owned 72,588 shares of the company’s stock, valued at $13,046,967.12. The trade was a 45.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Gilbert H. Kliman sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $190.00, for a total value of $475,000.00. Following the sale, the director directly owned 37,406 shares in the company, valued at $7,107,140. This trade represents a 6.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 82,500 shares of company stock valued at $14,862,000. Insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Glaukos

Several large investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in Glaukos in the second quarter worth about $1,333,318,000. Janus Henderson Group PLC increased its stake in Glaukos by 77.2% during the first quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock worth $575,844,000 after acquiring an additional 2,329,608 shares during the last quarter. Jupiter Topco LLC purchased a new stake in Glaukos during the second quarter valued at approximately $679,614,000. Primecap Management Co. CA purchased a new stake in Glaukos during the second quarter valued at approximately $424,969,000. Finally, William Blair Investment Management LLC bought a new stake in shares of Glaukos in the 2nd quarter valued at approximately $92,476,000. Institutional investors own 99.04% of the company’s stock.

Key Headlines Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Q3 results far exceeded expectations: Third-quarter revenue rose 58% year over year to approximately $211 million, well above the roughly $168 million analyst estimate. The company reported adjusted EPS of $0.47 versus consensus expectations for a loss of about $0.10–$0.12, compared with a $0.16 loss a year earlier. Glaukos Stock Charges Higher on Q3 Earnings Surprise
• Positive Sentiment: Profitability improved: Glaukos reported approximately $2 million in GAAP net income, or $0.03 per diluted share, marking a swing from a year-earlier loss. Operating cash flow was $14.8 million, and the company ended the quarter with $162.3 million in cash. Glaukos Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Sales outlook was raised: Management increased its 2026 revenue guidance to $775 million–$785 million from $680 million–$700 million and introduced a preliminary 2027 sales target of $1 billion. Investors viewed the outlook as evidence that iDose TR and Epioxa can sustain strong growth. Glaukos Sets $1 Billion 2027 Sales Goal
• Positive Sentiment: Analysts raised targets: JPMorgan lifted its target to $240 and retained an Overweight rating, while Needham raised its target to $251 with a Buy rating. BTIG, Stifel and Wells Fargo also increased their targets and maintained positive ratings. JPMorgan Analyst Recommendation
• Neutral Sentiment: Valuation has become demanding: The stock was trading near its 52-week high and above several newly raised analyst targets, including those from Wells Fargo, BTIG and Stifel, potentially limiting near-term upside despite bullish ratings.
• Negative Sentiment: Insider selling remains a risk signal: Data provided shows 32 open-market insider sales and no purchases over the past six months. The company also remains dependent on continued execution to meet its ambitious 2027 target.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.